Recent advances in management of COVID-19: A review
Under a Creative Commons license
open access
Graphical Abstract
Abbreviations
ADE
Antibody dependant enhancement of the disease
ARDS
Acute Respiratory Distress Syndrome
CDC
Centers for Disease Control and prevention
CoV
Coronavirus
COVID-19
Coronavirus disease-2019
CVT
Cerebral Venous Thrombosis
EC50
half maximum neutralization concentration
EUA
Emergency Use Authorization
FDA
Food and Drug Administration
IC50
Half maximal inhibitory concentration
IC90
Concentration that inhibits 90% of the virions
ICU
Intensive care unit
IL-6
Interleukin 6
IMP
Importin
IRE1
Inositol-requiring enzyme
1KD
Equilibrium dissociation constant (binding affinity)
LPS
Lipopolysaccharides
MERS
Middle East Respiratory Syndrome
Nbs
Nanobodies
NEJM
The New England Journal of Medicine
NIH
National Institutes of Health
NOS
Reactive nitrogen species
OTC
Over the Counter medication
PCR
Polymerase chain reaction
RBD
Receptor binding domain
RdRp
RNA-dependent RNA polymerase
ROS
Reactive oxygen species
S1R
Sigma 1 receptor
SARS
Severe Acute Respiratory Syndrome
SARS-CoV-2
Severe acute respiratory syndrome corona virus 2
sdNbs
Single domain nanobodies
SPR
Surface plasmon resonance
TMPRSS2
Transmembrane serine protease 2
TNF-alpha
Tumor Necrosis Factor alpha
WHO
World Health Organization
Keywords
COVID-19
SARS-CoV-2
Ivermectin
Famotidine
Nanobodies
Monoclonal antibodies
Remdesivir
SSRI
Fluvoxamine
Dexamethasone
Serotonin
Fluoxetine
Tocilizumab
Melatonin
Cited by (0)
© 2021 The Author(s). Published by Elsevier Masson SAS.